Food and Drug Administration (FDA) Medical Officer Robert Sh
UNITED STATES - APRIL 12: Food and Drug Administration (FDA) Medical Officer Robert Shibuya speaks about Merck & Co.'s experimental arthritis drug Arcoxia, at a Food and Drug Administration (FDA) Arthritis Advisory Committee Meeting, in Gaithersburg, Maryland, April 12, 2007. Arthritis Advisory Committee Center For Drug Evaluation and Research Members John C. Davis, of University of California, San Francisco, right, and Christy Sandborg, of Stanford University School of Medicine, left, listen. Arcoxia would be a ``a potential public health disaster'' if approved, said a U.S. regulator long critical of Vioxx, a predecessor that was withdrawn because of dangerous side effects. (Photo by Stephanie Kuykendal/Bloomberg via Getty Images)
PURCHASE A LICENCE
How can I use this image?
$650.00
AUD
DETAILS
Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloombergs prior written consent.
Credit:
Editorial #:
94650657
Collection:
Bloomberg
Date created:
12 April, 2007
Upload date:
Licence type:
Release info:
Not released. More information
Source:
Bloomberg
Object name:
pdir0814\PHi_j0088.JPG